Biotech developing complement-pathway inhibitors (narsoplimab) for rare blood and transplant-related diseases.
Biotech developing complement-pathway inhibitors (narsoplimab) for rare blood and transplant-related diseases.
Has no product of its own on sale after selling its Omidria eye-surgery drug in 2021, so it funds development from capital it raises and from deals tied to that sale. Revenue from narsoplimab would start only if regulators approve it.
Moat: narrow (IP / patents). MASP-2-targeted mechanism is differentiated from complement C5 inhibitors used by rivals.
Headquarters: Seattle, Washington, US · Founded: 1994 · Employees: 175
Size Omeros (OMER) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.08B, the 2178th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.55 on 18 Nov 2026.
Performance Over six months the shares gained 24.4%, against -9.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth The operating margin is -56.4% (peer median 8.9%).
Valuation It trades at 4.3× forward earnings against a peer median of 18.2× (cheapest of 15).
Capital Return on invested capital runs 47.0 points below its cost of capital (16.8% WACC).
Short interest Short interest is 17.7% of the free float (30 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $74.4M | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $71.3M | -$964,000 | -$950,000 | -$920,000 | -$952,000 |
| EBITDA | -$41.1M | -$122M | -$168M | -$164M | -$162M |
| Net income | $98.4M | -$3.35M | -$157M | -$118M | $47.4M |
| Free cash flow | -$43.4M | -$123M | -$149M | $74.3M | -$86.6M |
| Capital expenditure | $70,000 | $65,000 | $165,000 | $426,000 | $113,000 |
| Total debt | $295M | $407M | $423M | $362M | $468M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Omeros OMER | $1.08B | +24% | n/a | -56% | 4.3× | n/a |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OMER | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.1% | -1.1% | 5th lowest of 21 |
| 6-month return | +24.4% | -9.7% | 3rd highest of 20 |
| Distance from 52-week high | -31.5% | -26.8% | 10th lowest of 21 |
| Operating margin | -56.4% | 8.9% | 2nd lowest of 18 |
| Forward P/E | 4.3× | 18.2× | cheapest of 15 |
| ROIC minus cost of capital | -47.0 pp | -0.2 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |